Vaxart
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Vaxart sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Vaxart: 19 sponsored US clinical trials, none currently recruiting.
Vaxart sponsors 19 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 16 completed. 0 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is COVID-19, with 2 trials.
Top-decile sponsor footprint
Vaxart ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
19 total, page 1 of 1
A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old
NCT06944717
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055
A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
NCT05626803
A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers
NCT05213728
Norovirus Challenge Study
NCT05212168
A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine
NCT05067933
Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines
NCT04875676
Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine
NCT04854746
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
NCT04563702
Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines
NCT03897309
Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
NCT03125473
Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults
NCT03121339
A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
NCT02918006
Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine
NCT02868073
Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)
NCT02830932
Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum
NCT01761123
Safety Study of an Oral Vaccine to Prevent Seasonal Influenza
NCT01688297
Immunogenicity of ND1.1 by Delivery Directly to the Ileum
NCT01698060
Safety Study of an Oral Vaccine to Prevent Avian Influenza
NCT01335347
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 4 |
Therapeutic Areas
How the Vaxart early-phase archive is shaped
19 indexed studies, none listed as recruiting (0% open); 16 completed (84%).
Phase mix: 0 late (III/IV) vs 19 early (I/II) (early-phase heavy).
Top condition: COVID-19 (2 trials), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Vaxart: archived-pipeline peers nationwide
Peers matched on 19 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Vaxart sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 archived trials
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Vaxart page
19 registered trials is a research-attention snapshot, not an endorsement of Vaxart or any single study.
- None of Vaxart's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- COVID-19 is the condition Vaxart studies most, compare against other sponsors active in the same condition before evaluating a specific study. See COVID-19 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Vaxart pipeline card: 19 registered trials from official public datasets.Report a data error.